Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 122.23B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 14.54 |
| Forward PE | 8.62 |
| Dividend | 1.53 (7.09%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 2,178 |
| Average Volume | 14,754 |
| Open | 21.68 |
| Previous Close | 21.61 |
| Day's Range | 21.49 - 21.68 |
| 52-Week Range | 18.77 - 26.50 |
| Beta | n/a |
| RSI | 46.91 |
| Earnings Date | Feb 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
UST–IIT Madras partnership aims to speed up healthcare startup growth
UST and IIT Madras Incubation Cell have partnered to accelerate deep-tech healthcare and life sciences startups. This collaboration will identify, mentor, and fund promising ventures, aiming to transl...
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Better Buy in 2026: Pfizer or Merck?
This year has been one to forget for these pharmaceutical giants.
Watch live: Trump to deliver announcement on drug pricing
President Trump on Friday afternoon will make an announcement related to lowering drug prices — an effort he has leaned into ahead of the 2026 midterm elections. In recent months, Trump has struck dea...
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Validea Detailed Fundamental Analysis - PFE
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of Me...
Pfizer signs exclusive 5-year supply and marketing pact with Cipla for four key brands
Pfizer Limited on Thursday announced that it has entered into an exclusive supply and marketing agreement with Cipla for four...
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now
These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.
Better Buy in 2026: Pfizer or Eli Lilly?
These two stocks have been going in opposite directions over the past few years.
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpo...
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways: With the drug still at an earl...
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal
Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer
(RTTNews) - Astellas Pharma Inc. and Pfizer Inc. announced positive topline results from the Phase 3 EV-304 clinical trial (KEYNOTE-B15), evaluating PADCEV (enfortumab vedotin), a Nectin-4 directed an...
Lightning Round: I would buy M&T Bank tomorrow morning, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Pfizer, Elanco, Rocket Lab, Lithium Americas, Daktronics, Diageo, and more.
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Pfizer Stock Can Sink More. Here Is How
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
If I Could Only Buy and Hold a Single Stock, This Would Be It
Lower demand for COVID-19 treatments has been hurting Pfizer's revenue. Pfizer also has major products losing patent protection over the next couple of years.
Pfizer: Ignoring The Dead Cat Bounce
Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield. Read more on PFE stock here.
Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.
Morgan Stanley Lowers Pfizer (PFE) Price Target to $27.00 | PFE Stock News
Morgan Stanley Lowers Pfizer (PFE) Price Target to $27.00 | PFE Stock News
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this mon...